Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio

被引：0
|
作者：
Stephen Sun
Suzanne Heske
Melanie Mercadel
Jean Wimmer
机构：
[1] Syneos Health,
来源：
Therapeutic Innovation & Regulatory Science | 2021年 / 55卷
关键词：
FDA; Benefit–risk framework; Net-benefit; Scoring; Risk management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：129 / 137
页数：8
相关论文
共 20 条
  • [11] A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework
    Jane Namangolwa Mutanga
    Ujwani Nukala
    Marisabel Rodriguez Messan
    Osman N. Yogurtcu
    Quinn McCormick
    Zuben E. Sauna
    Barbee I. Whitaker
    Richard A. Forshee
    Hong Yang
    [J]. The AAPS Journal, 25
  • [12] A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA's Benefit-Risk Framework
    Mutanga, Jane Namangolwa
    Nukala, Ujwani
    Rodriguez Messan, Marisabel
    Yogurtcu, Osman N.
    McCormick, Quinn
    Sauna, Zuben E.
    Whitaker, Barbee I.
    Forshee, Richard A.
    Yang, Hong
    [J]. AAPS JOURNAL, 2023, 25 (01):
  • [13] Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial
    Marston, Nicholas A.
    Kamanu, Frederick K.
    Nordio, Francesco
    Gurmu, Yared
    Roselli, Carolina
    Sever, Peter S.
    Pedersen, Terje R.
    Keech, Anthony C.
    Wang, Huei
    Pineda, Armando Lira
    Giugliano, Robert P.
    Lubitz, Steven A.
    Ellinor, Patrick T.
    Sabatine, Marc S.
    Ruff, Christian T.
    [J]. CIRCULATION, 2020, 141 (08) : 616 - 623
  • [14] Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease
    Catt, Heather
    Hughes, Dyfrig
    Bodger, Keith
    Kirkham, Jamie
    [J]. TRIALS, 2017, 18
  • [15] Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease: Using a Genetic Risk Score (vol 141, pg 616, 2019)
    Marston
    [J]. CIRCULATION, 2024, 149 (24) : e1414 - e1414
  • [16] A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan
    Wolter, Kevin D.
    Kamatani, Asayuki
    Suzuki, Yumiko
    Imaeda, Takayuki
    Dagher, Ramzi
    Safferman, Allan
    Junor, Rod
    [J]. PHARMACEUTICAL MEDICINE, 2024, 38 (03) : 217 - 224
  • [17] A Sponsor’s Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan
    Kevin D. Wolter
    Asayuki Kamatani
    Yumiko Suzuki
    Takayuki Imaeda
    Ramzi Dagher
    Allan Safferman
    Rod Junor
    [J]. Pharmaceutical Medicine, 2024, 38 : 217 - 224
  • [18] A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach
    Gomeni, Roberto
    Fang, Lanyan
    Bressolle-Gomeni, Francoise
    Spencer, Thomas J.
    Faraone, Stephen V.
    Babiskin, Andrew
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (02): : 97 - 106
  • [19] A COST-UTILITY ANALYSIS OF THE RISK MODEL-GUIDED ANTIEMETIC PROPHYLAXIS VERSUS PHYSICIAN'S CHOICE IN PATIENTS RECEIVING CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER: A NET-BENEFIT REGRESSION APPROACH
    Thavorn, K.
    Vandermeer, L.
    Mazzarello, S.
    Wang, Z.
    Clemons, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A890 - A890
  • [20] Net Clinical Benefit of Prehospital Glycoprotein IIb/IIIa Inhibitors in Patients with ST-Elevation Myocardial Infarction and High Risk of Bleeding: Effect of Tirofiban in Patients at High Risk of Bleeding Using CRUSADE Bleeding Score
    Hermanides, Renicus S.
    Ottervanger, Jan Paul
    ten Berg, Jurrien M.
    Gosselink, A. T. Marcel
    van Houwelingen, Gert
    Dambrink, Jan-Henk E.
    Stella, Pieter R.
    Hamm, Christian
    van 't Hof, Arnoud W. J.
    [J]. JOURNAL OF INVASIVE CARDIOLOGY, 2012, 24 (03): : 84 - 89
12